titanium dioxide and talc, Fipaxalparant clinical trials

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]

This study is testing a new medicine, Fipaxalparant, for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It aims to see if the medicine can improve lung function and other symptoms over about a year.